These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Poly(2-hydroxyethyl methacrylate)/β-cyclodextrin-hyaluronan contact lens with tear protein adsorption resistance and sustained drug delivery for ophthalmic diseases. Li R; Guan X; Lin X; Guan P; Zhang X; Rao Z; Du L; Zhao J; Rong J; Zhao J Acta Biomater; 2020 Jul; 110():105-118. PubMed ID: 32339710 [TBL] [Abstract][Full Text] [Related]
23. Multiple drug delivery from the drug-implants-laden silicone contact lens: Addressing the issue of burst drug release. Desai AR; Maulvi FA; Desai DM; Shukla MR; Ranch KM; Vyas BA; Shah SA; Sandeman S; Shah DO Mater Sci Eng C Mater Biol Appl; 2020 Jul; 112():110885. PubMed ID: 32409042 [TBL] [Abstract][Full Text] [Related]
25. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye. Natarajan JV; Ang M; Darwitan A; Chattopadhyay S; Wong TT; Venkatraman SS Int J Nanomedicine; 2012; 7():123-31. PubMed ID: 22275828 [TBL] [Abstract][Full Text] [Related]
26. [In vitro evaluation for corneal damages by anti-glaucoma combination eye drops using human corneal epithelial cell (HCE-T)]. Nagai N; Murao T; Oe K; Ito Y; Okamoto N; Shimomura Y Yakugaku Zasshi; 2011; 131(6):985-91. PubMed ID: 21628988 [TBL] [Abstract][Full Text] [Related]
27. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study. Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918 [TBL] [Abstract][Full Text] [Related]
28. Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis. Harasymowycz P; Hutnik C; Rouland JF; Negrete FJM; Economou MA; Denis P; Baudouin C Adv Ther; 2021 Jun; 38(6):3019-3031. PubMed ID: 33891269 [TBL] [Abstract][Full Text] [Related]
29. Development of Timolol-Loaded Galactosylated Chitosan Nanoparticles and Evaluation of Their Potential for Ocular Drug Delivery. Zhao R; Li J; Wang J; Yin Z; Zhu Y; Liu W AAPS PharmSciTech; 2017 May; 18(4):997-1008. PubMed ID: 28101726 [TBL] [Abstract][Full Text] [Related]
31. Lollipop-Inspired Multilayered Drug Delivery Hydrogel for Dual Effective, Long-Term, and NIR-Defined Glaucoma Treatment. Wang F; Song Y; Huang J; Wu B; Wang Y; Pang Y; Zhang W; Zhu Z; Ma F; Wang X; Zhang X Macromol Biosci; 2021 Nov; 21(11):e2100202. PubMed ID: 34405963 [TBL] [Abstract][Full Text] [Related]
32. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug. Sharif NA Curr Opin Pharmacol; 2024 Feb; 74():102426. PubMed ID: 38168596 [TBL] [Abstract][Full Text] [Related]
33. Latanoprost : an update of its use in glaucoma and ocular hypertension. Perry CM; McGavin JK; Culy CR; Ibbotson T Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627 [TBL] [Abstract][Full Text] [Related]
34. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study. Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719 [TBL] [Abstract][Full Text] [Related]
35. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group. Diestelhorst M Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Shin DH; Feldman RM; Sheu WP; Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375 [TBL] [Abstract][Full Text] [Related]
37. The Effect of Therapeutic IOP-lowering Interventions on the 24-hour Ocular Dimensional Profile Recorded With a Sensing Contact Lens. Cutolo CA; De Moraes CG; Liebmann JM; Mansouri K; Traverso CE; Ritch R; J Glaucoma; 2019 Mar; 28(3):252-257. PubMed ID: 30640804 [TBL] [Abstract][Full Text] [Related]